Results 361 to 370 of about 303,514 (383)
Some of the next articles are maybe not open access.

Metformin and Fibrinolysis

Scandinavian Journal of Haematology, 1969
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire   +3 more sources

Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation

Diabetes & Metabolism, 2014
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
Rachel Desailloud   +4 more
openaire   +3 more sources

Rosiglitazone/Metformin

Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire   +3 more sources

Metformin

2022
Berta, Margaret   +5 more
openaire   +1 more source

Pharmacogenetics of Metformin

2016
Metformin is the most widely prescribed antidiabetic drug in the world. Despite its beneficial effects in reducing the risk for developing vascular complications associated with diabetes, the glycemic response to metformin is highly variable. Genetic factors, along with factors such as various comorbidities and body weight, contribute to this ...
Yee, Sook Wah   +2 more
openaire   +3 more sources

Metformin

New England Journal of Medicine, 1996
C J, Bailey, R C, Turner
openaire   +2 more sources

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

The Lancet, 1998
R. Turner   +13 more
semanticscholar   +1 more source

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

Nature Network Boston, 2017
Hao Wu   +17 more
semanticscholar   +1 more source

[Metformin and kidney].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2016
Metformin is the first choice among drugs used for the treatment of type II diabetes mellitus mainly because of several advantages: proven hypoglycemic effect, good safety profile, virtually no risk of hypoglycemia, body weight reduction, lipid-lowering effect, efficacy in preventing micro- and macrovascular complications as well as adverse cardiac and
Sessa C   +5 more
openaire   +2 more sources

Metformin☆

2007
Caroline Day, Clifford J. Bailey
openaire   +1 more source

Home - About - Disclaimer - Privacy